Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes

Dow Jones

Nov 02, 2024

By Sabela Ojea

Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.

Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month.

Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said.

The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said.

Myriad Genetics wasn't immediately available for comment.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

November 01, 2024 12:34 ET (16:34 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2480776831"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480776831\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2480776831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-02 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480776831","market":"us","top_or_hot":-1,"title":"Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. \n</p>\n<p>\n  Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n</p>\n<p>\n  The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said. \n</p>\n<p>\n  Myriad Genetics wasn't immediately available for comment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 12:34 ET (16:34 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-02 00:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. \n</p>\n<p>\n  Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n</p>\n<p>\n  The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said. \n</p>\n<p>\n  Myriad Genetics wasn't immediately available for comment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 12:34 ET (16:34 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2480776831","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480776831","pubTimestamp":1730478840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month.Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said.The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MYGN":"万基遗传"},"translate_title":"UnitedHealthcare承保范围变化导致Myriad Genetics股价下跌21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n\n\n  Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. \n\n\n  Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n\n\n  The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said. \n\n\n  Myriad Genetics wasn't immediately available for comment. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 01, 2024 12:34 ET (16:34 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}